Denosumab versus zoledronic acid in cases of surgically unsalvageable giant cell tumor of bone: A randomized clinical trial

Yue, Jiaji; Sun, Wei; Li, Shenglong

doi:10.1016/j.jbo.2022.100441

Cited by 15 publications

(14 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bisphosphonate has shown a promising result in treating metastases of GCT. The anti-osteoclast effect of bisphosphonates and their ability to prevent bone resorption make bisphosphonates a potential treatment for GCT, and several studies have confirmed its efficacy [10]. However, in this study the patient had a recurring case of GCT in the left ankle based on clinical symptoms and radiographic examination.…”

Section: Discussionmentioning

confidence: 58%

“…The binding affinity of zoledronic acid for hydroxyapatite was higher than that of other bisphosphonates (binding affinity constants of 3.47 9 10 -6 mol/L vs. 2.94, 2.36, 2.19, 1.19 and 0.72 9 10 -6 mol/L for alendronic acid, ibandronic acid, risedronic acid, etidronic acid, and clodronic acid, respectively) [9]. Zoledronic acid has also been considered a reasonable, effective treatment for unresectable lesions [7,10].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Bisphosphonate treatment as a safe choice for treating lung metastases of recurrent giant cell tumor of bone

2023

View full text Add to dashboard Cite

Giant cell tumor (GCT) accounts for 5% of all primary bone tumors and 20% of benign skeletal tumors. This case report presents the case of a 17-year-old female with a recurrent giant cell tumor and lung metastases. The patient received bisphosphonate therapy instead of surgery. The use of zoledronic acid for lung metastases from GCT may have conservatively improved clinical symptoms and radiological assessments can be achieved.

show abstract

Section: Discussionmentioning

confidence: 58%

Section: Discussionmentioning

confidence: 99%

Bisphosphonate treatment as a safe choice for treating lung metastases of recurrent giant cell tumor of bone

2023

View full text Add to dashboard Cite

show abstract

“…There are studies that say that denosumab and zoledronic acid have similar tumor responses and clinical benefits. Denosumab is a safe but costly alternative to zoledronic acid for treatment of surgically unsalvageable GCT (30). These treatments are used in cases of GCT.…”

Section: Discussionmentioning

confidence: 99%

Giant cell tumor of the bone: an evaluation of prognostic factors associated with local recurrence and a comparison with the current literature

Karadeniz

Yurtbay

Erdoğan

et al. 2022

Anatolian Current Medical Journal

View full text Add to dashboard Cite

Aim: Results of the surgical and medical treatments of giant cell tumor of the bone (GCT) in terms of local recurrence and prognostic factors associated with local recurrence are evaluated in this study. Material and Method: Patients treated with either surgical or medical methods for GCT between 2011 and 2021 were retrospectively evaluated. Gender and age of the patients, localization of tumors, the existence of pathological fractures, grade of the tumor, soft tissue expansion, and resection types were evaluated. Postoperative local recurrence and metastasis were analyzed, and the risk factors associated with local recurrence were determined. Results: The mean age of the 117 patients (51 female and 66 male) was 36.1±9.3 years. The mean follow-up was 71.2±48.3 months. Forty patients were Grade I, 56 were Grade II, and 21 were Grade 3, according to the Campanacci Grading System. Soft tissue expansion was present in 21 (17.9%) patients. 59.8% of the patients were undergone intralesional curettage, 32.4% of the patients were treated with marginal or wide local excision combined with adjuvant therapy with liquid nitrogen and poly-methyl methacrylate (PMMA) application, and 5.9% of the patients have treated with en bloc wide resection and reconstruction or arthrodesis. Two patients suffering from sacral involvement were treated with radiotherapy. There was local recurrence after surgery in 19 (16.2%) of the patients. Conclusion: Local recurrence is an important cause of morbidity in the treatment of GCT, which is a benign but aggressive tumor of the bone. In this study, in which we investigated the causes of local recurrence, Campanacci Grade and soft tissue expansion were found to be associated with the development of local recurrence.

show abstract

“…Numerous basic and clinical studies have shown that denosumab is clinically beneficial for the treatment of advanced or metastatic GCTB [ 21 , 22 ]. However, various controversies regarding its use as a pre-operative adjuvant therapy prevail.…”

Section: Introductionmentioning

confidence: 99%

Progress on Denosumab Use in Giant Cell Tumor of Bone: Dose and Duration of Therapy

Xiang

Liu

Deng

et al. 2022

Cancers

View full text Add to dashboard Cite

Giant cell tumor of bone (GCTB) is an aggressive non-cancerous bone tumor associated with risks of sarcoma and metastasis. Once malignancy occurs, the prognosis is generally poor. Surgery remains the main treatment for GCTB. Multidisciplinary management is a feasible option for patients wherein surgical resection is not an option or for those with serious surgery-related complications. Denosumab is an anti-nuclear factor kappa B ligand approved for the treatment of postmenopausal women with osteoporosis, bone metastases, and advanced or inoperable GCTB. However, the guidelines for treating GCTB are unclear; its short-term efficacy and safety in inoperable patients have been demonstrated. Lengthier therapies (high cumulative doses) or pre-operative adjuvant therapy may be associated with severe complications and high local recurrence rates. Short-term administration helps attain satisfactory local control and functionality. As a result, lately, the impact of different doses and lengths of treatment on the efficacy of denosumab in GCTB treatment, the incidence of complications, and recurrence rates have gained attention. The efficacy and safety of denosumab against GCTB, its impact on imaging assessment, related complications, and recurrence of GCTB were previously reviewed. For further research direction, this paper reviews the progress of studies evaluating the impact of the dose and duration of denosumab therapy for GCTB.

show abstract

Denosumab versus zoledronic acid in cases of surgically unsalvageable giant cell tumor of bone: A randomized clinical trial

Cited by 15 publications

References 28 publications

Bisphosphonate treatment as a safe choice for treating lung metastases of recurrent giant cell tumor of bone

Bisphosphonate treatment as a safe choice for treating lung metastases of recurrent giant cell tumor of bone

Giant cell tumor of the bone: an evaluation of prognostic factors associated with local recurrence and a comparison with the current literature

Progress on Denosumab Use in Giant Cell Tumor of Bone: Dose and Duration of Therapy

Contact Info

Product

Resources

About